Document is current
Any future updates will be listed below
-
Authors
Stögbauer, Fabian https://orcid.org/0000-0002-8897-5165
Wirth, Markus
Lauterbach, Maren
Wollenberg, Barbara
Schmidl, Benedikt
Hoch, Cosima C. https://orcid.org/0000-0002-3875-7389
Ourailidis, Iordanis https://orcid.org/0000-0001-6783-5617
Hess, Jochen https://orcid.org/0000-0003-3493-1711
Eckstein, Markus https://orcid.org/0000-0001-5418-3349
Hartmann, Arndt
Iro, Heinrich
Gostian, Antoniu-Oreste
Balk, Matthias
Jesinghaus, Moritz
Ribbat-Idel, Julika
Sailer, Verena-Wilbeth
Perner, Sven
Bruchhage, Karl-Ludwig
Hoffmann, Markus
Lükewille, Lukas
Stuhlmann-Laeisz, Christiane Maria
Röcken, Christoph https://orcid.org/0000-0002-6989-8002
Mogler, Carolin
Budczies, Jan https://orcid.org/0000-0002-6668-5327
Boxberg, Melanie https://orcid.org/0000-0001-5989-7922
- License Information
-
More Information
Article History
Received: 9 February 2024
Revised: 21 October 2024
Accepted: 12 November 2024
First Online: 29 November 2024
Competing interests
: FS: No conflict of interest. MW: No conflict of interest. ML: Is a member of DKTK school of oncology and received funding from DKFZ Clinical Scientist Program (H70). BW: No conflict of interest. BS: No conflict of interest. CCH: No conflict of interest. IO: No conflict of interest. JH: No conflict of interest. ME: Research funding from the Else Kröner-Fresenius Foundation/EKFS (2020_EKEA.129; 2023_EKES.07), the TOPeCS funding line of the IZKF (IZKF-FAU T04) of the FAU, an advanced research grant of the IZKF of the FAU Erlangen-Nürnberg (IZKF-FAU D41) and a Young Clinical Scientist Fellowship of the Bavarian Center for Cancer Research (BZKF; YSF-TP01). Declares Personal fees, travel costs and speaker’s honoraria from MSD, AstraZeneca, Janssen-Cilag, Cepheid, Diaceutics; research funding from AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead; advisory roles for Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth and Gilead. AH: No conflict of interest. HI: No conflict of interest. AOG: No conflict of interest. MBa: No conflict of interest. MJ: No conflict of interest. JRI: Funding from University of Luebeck, Habilitation Grant (H01-2022). VWS: No conflict of interest. SP: No conflict of interest. KLB: No conflict of interest. MH: No conflict of interest. LL: No conflict of interest. CMSL:No conflict of interest. CR: No conflict of interest. CM: No conflict of interest. JB: Funding from Deutsche Krebshilfe (German Cancer Aid), Consulting: MSD. MBo: Funding from Deutsche Krebshilfe (German Cancer Aid), Else Kröner Fresenius Stiftung. Funding for Research: BMS. Advisory Boards and speakers’ fees: BMS, MSD, Trillium Akademie
: The analyses were conducted with participants’ consents and in accordance with the declaration of Helsinki. An ethics vote by the local ethics committees was obtained: Friedrich-Alexander University Erlangen- Nuremberg: 23- 22- Br, University of Heidelberg: S-680/2021, University of Lübeck: AZ 16-277 and Technical University of Munich: 2023-543-S-SB. An ethics vote was not deemed necessary for the Christian-Albrechts-Universität zu Kiel due to the anonymized retrospective nature of the data.
